5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrole-3-carbaldehyde, C16H11FN2O3S, relative molecular mass 330.34 g/mol, is released as a pharmaceutical-grade active pharmaceutical ingredient for oral solid dosage forms—tablet, capsule, and granule—and for injectable formulations requiring aseptic or terminally sterilized manufacture. The molecule combines a pyrrole-3-carbaldehyde core with a pyridin-3-ylsulfonyl substituent at the 1-position and a 2-fluorophenyl group at the 5-position. The electron-withdrawing sulfonyl group lowers pyrrole ring electron density, while the C3 aldehyde remains reactive toward primary amines, hydrazines, and strong nucleophiles. These structural features define the analytical strategy, excipient compatibility limits, and packaging controls. Because the substance is not the subject of a current Ph Eur or USP monograph, release specifications are derived from ICH Q6A decision tree #1 for new chemical entities, supported by ICH Q3A, ICH Q3C, ICH Q3D, and ICH Q2(R1) validation procedures. Where a manufacturer-specific lot code is assigned, that code functions only as a synthetic-campaign traceability identifier and is not a compendial identity marker.

For direct compression, a jet-milled lot with a D90 of ≤ 25 µm is often screened because aldehyde-containing crystals may exhibit acicular habit and low bulk density. Dry granulation is preferred over wet granulation when water uptake accelerates aldehyde hydration or degradation; where wet granulation is unavoidable, the granulating fluid must be free of primary amines and the granulation endpoint is typically controlled below 3.0% w/w residual moisture. Injectable-grade material is not interchangeable with oral-grade material solely on chemical assay; it carries additional bioburden, bacterial endotoxin, particulate matter, and container-closure compatibility obligations.

What Physicochemical Assay Windows Define Release for This Pyrrole-3-carbaldehyde?

Assay is conducted by reversed-phase HPLC with ultraviolet detection; the detection wavelength is selected from the compound’s absorbance maximum and system suitability is verified under USP <621> or Ph Eur 2.2.46. A release specification commonly applies an assay boundary of 98.0% to 102.0% calculated on the anhydrous, solvent-free basis. Related substances are controlled at an unspecified impurity limit of 0.10% and a total impurity limit of 0.50%, consistent with ICH Q3A. For injectable-grade material, the same chemically derived acceptance limits remain, but additional microbiological and particulate tests apply.

Typical system suitability criteria include resolution between the aldehyde and its oxidative degradation product of not less than 2.0, tailing factor not more than 1.5, and injection repeatability not more than 1.0% relative standard deviation for assay standard injections. The aldehyde peak is evaluated for peak purity by diode-array or mass spectrometry; any coeluting impurity above the reporting threshold triggers method adjustment under ICH Q2(R1) and USP <621> allowable adjustments. Residual solvent control follows ICH Q3C; class 1 solvents are excluded from the synthetic route, and class 2 solvents are validated below their permitted daily exposure. Injectable-grade lots are released against a tighter internal limit, often capped at 50% of the ICH Q3C permitted daily exposure, because injectable delivery bypasses first-pass metabolism. Elemental impurities are controlled by ICH Q3D Option 1; if the product is used in high daily doses, the permitted concentration is calculated from the ICH Q3D permitted daily exposure by dividing by the maximum daily dose.

Stability-indicating HPLC methods are validated under ICH Q2(R1) and ICH Q1A(R2). The API is stressed in 0.1 M hydrochloric acid, 0.1 M sodium hydroxide, 3% hydrogen peroxide, dry heat, and ICH Q1B photolytic conditions. Mass balance between assay and total degradation products is expected to be not less than 95%. Published data for this exact chemical configuration are limited; therefore the specification dossier relies on route-specific batch data and forced degradation profiles generated on three consecutive production-scale batches. The aldehyde is most sensitive to oxidative and alkaline stress; the major degradation route is conversion to the corresponding carboxylic acid, which is monitored by relative retention time. Aqueous sample diluents are prepared immediately before injection because the aldehyde may form geminal diol or hemiacetal adducts in protic media.

The table below summarizes a representative quality-control framework; actual lot-specific acceptance criteria are established in the approved specification and may vary by manufacturing route and intended dose.

Milling and compression operations are controlled because the aldehyde-containing crystals may exhibit brittle fracture and low bulk density. An instrumented rotary tablet press with pre-compression roller is used to generate compressibility, compactibility, and tabletability profiles; ejection force, die-wall friction, and compaction pressure are logged to identify direct-compression limits. For dry granulation, roller compaction with a gap-controlled roller compactor and integrated sieve mill is preferred over slugging because it provides tighter granule density control and reduces fines. For capsule filling, the D90 and bulk density are specified to maintain weight uniformity under USP <905> or Ph Eur 2.9.5.

Excipient selection is constrained by the free aldehyde. Primary amines, hydrazines, and amino-sugar excipients can form Schiff-base adducts; buffers containing ammonia or tromethamine are avoided. Reducing sugars such as lactose may be used only after a formal compatibility study because aldehyde-amine condensation can occur with minor amine impurities or with degradation products; mannitol, microcrystalline cellulose, dibasic calcium phosphate dihydrate, and low-peroxide cross-linked polyvinylpyrrolidone are generally preferred. High-moisture granulation and prolonged exposure to alkaline granulating fluids are avoided because the aldehyde can undergo Cannizzaro-type disproportionation or oxidation under strong alkali. For tablet film coating, a low-temperature, non-aqueous or hydroalcoholic coating system is preferred to limit moisture exposure.

Particle Size, Aldehyde Reactivity, and Excipient Compatibility Limits

Powder flow is characterized by Hausner ratio and shear cell testing. Direct-compression blends containing more than 20% w/w of a poorly flowing API are generally considered high risk; if the Hausner ratio exceeds 1.35, a dry granulation step is usually introduced. The API lot is classified by bulk density, tapped density, and compressibility index under USP <616>; the acceptance range is set to ensure capsule weight variation and tablet content uniformity under USP <905>.

For oral granule manufacture, the API is pre-blended with a non-reducing diluent before high-shear granulation; the binder solution is added at low impeller speed to avoid localized overheating. If the formulation requires wet granulation, the granule moisture is monitored by loss-on-drying at 105 °C to an endpoint below 3.0% w/w. For tablets that exhibit poor flow, glidant levels are optimized by measuring bulk density, tapped density, Carr index, and Hausner ratio under Ph Eur 2.9.34 or USP <616>. Compression force is adjusted only after compaction profile data confirm that higher pressure does not reduce dissolution. Granule formulations are manufactured by low-shear or high-shear wet granulation; for high-shear granulation, impeller speed and chopper speed are evaluated by design of experiments. The impeller tip speed is typically kept below 10 m/s to avoid over-granulation and localized heating. The wet mass is dried in a fluidized-bed dryer with inlet air temperature controlled below 50 °C if the aldehyde is thermally labile; final granule moisture is verified by Karl Fischer or loss on drying. For dry granulation, roll compaction pressure and roll speed are adjusted to achieve a ribbon solid fraction between 0.5 and 0.7; this range is often appropriate for brittle APIs but must be confirmed experimentally.

Although the API itself is not a dosage form, drug product dissolution is assessed under USP <711> or Ph Eur 2.9.3. The aldehyde-containing molecule may show pH-dependent dissolution because the pyridine nitrogen can be protonated in acidic media; dissolution testing in 0.1 M hydrochloric acid, pH 4.5 acetate buffer, and pH 6.8 phosphate buffer is used to evaluate oral formulations. If the API is milled to D90 ≤ 25 µm, dissolution is typically controlled by particle size and wetting agent concentration rather than by polymorphic transformation; however, polymorph conversion during milling should be excluded by X-ray powder diffraction.

When Injectable-Grade Controls Require Terminal Sterilization or Aseptic Processing

Injectable development begins with solubility screening in pH 3.0 to 7.4 buffered media; the free aldehyde is non-ionizable, so solubility depends on the lipophilic 2-fluorophenyl and pyridin-3-ylsulfonyl substituents rather than salt formation. Where solubility is insufficient for solution injection, micronization or lyophilized formulation approaches may be assessed; however, published data for this exact chemical configuration are limited, and feasibility must be confirmed experimentally. Terminal steam sterilization at 121 °C is evaluated only if the aldehyde degradation profile remains within ICH Q3B thresholds; the aldehyde may undergo thermal oxidation or condensation with any low-molecular-weight amine impurity. Aseptic filtration through a validated 0.22 µm PVDF or polyethersulfone filter is common for thermolabile neutral molecules, provided filter compatibility and extractables/leachables are evaluated under ICH Q3C and relevant regulatory guidance such as PDA Technical Report 26.

For injectable products, bacterial endotoxin limits are calculated from the maximum dose: a common limit is 0.25 EU/mg or 0.50 EU/mg depending on dose and route; if the maximum dose is high, the limit is derived from 5 EU/kg of body weight per hour. Sterility is demonstrated by membrane filtration under USP <71> or Ph Eur 2.6.1; particulate matter is controlled by light obscuration under USP <788> and Ph Eur 2.9.19. The API is usually sterilized by filtration and then lyophilized or filled aseptically; terminal gamma irradiation is not routinely used because electron-rich pyrrole and aldehyde moieties may generate free radicals and degradation products.

For injectable solution, pH adjustment with hydrochloric acid or sodium hydroxide may be required, but the aldehyde must be kept below pH 8.0 to avoid alkaline decomposition. Organic cosolvents such as propylene glycol, ethanol, or dimethylacetamide may be screened; each solvent must be controlled to ICH Q3C limits and monitored for peroxide content. If the solution is to be lyophilized, the formulation is characterized by collapse temperature and glass transition temperature of the frozen matrix; the primary drying shelf temperature is set below the collapse temperature, and the chamber pressure is controlled in the range of 50–150 mTorr for typical laboratory-scale lyophilizers. These values are equipment-specific and require cycle validation.

Filter compatibility studies measure the API loss across the membrane and the release of extractables. The filtration step is run under differential pressure below the filter manufacturer’s maximum; for viscous or cosolvent-containing solutions, a PVDF membrane is often preferred because of low protein binding and broad solvent compatibility. The bubble point, diffusion test, and water intrusion test are performed according to the filter manufacturer’s validation guide and ISO 29463 for air filters where applicable. For injectable packaging, glass vials with elastomeric closures are selected after extractables and leachables study. The aldehyde may react with sulfite-based antioxidants or amine-containing stopper accelerators; therefore stoppers with low extractable amine and oxidant profiles are preferred. Headspace oxygen is controlled by nitrogen flushing; residual oxygen in the headspace is commonly specified below 2% v/v for oxygen-sensitive products.

Compared with carboxylate salt forms intended for lyophilization, this molecule contains no sodium or potassium counterion; therefore it does not contribute to the total cation load of a fixed-dose combination. Compared with a simple 5-phenylpyrrole-3-carbaldehyde analogue, the ortho-fluorine substituent on the phenyl ring increases lipophilicity and alters crystal packing, while the pyridin-3-ylsulfonyl group introduces a basic pyridine nitrogen that can be protonated in acidic gastric fluid and may be exploited for pH-dependent dissolution design. Compared with aliphatic aldehyde APIs, the conjugated pyrrole system reduces aldehyde volatility and shifts oxidative degradation products toward polar carboxylic acid derivatives; this changes containment and impurity tracking but does not remove the need for oxygen-barrier packaging.

Technical-grade material is not interchangeable with pharmaceutical-grade API even when the chromatographic purity is similar. Pharma grade requires ICH M7 assessment for mutagenic impurities, including potential sulfonate esters if sulfonic acid activation steps are present; batch release implies absence of cross-contamination from equipment sharing, validated cleaning acceptance limits, and a documented change-control system under 21 CFR 210 and 21 CFR 211 for the relevant manufacturing steps. For injectable use, the raw material must also meet current good manufacturing practice requirements for sterile API or be further processed under aseptic conditions by the drug product manufacturer.

Bulk API is packaged in double low-density polyethylene bags inside a sealed aluminium foil laminate, with nitrogen overlay where long-term stability data show oxygen sensitivity. Storage is assigned under ICH Q1A(R2) long-term conditions; if no zone IVb requirement applies, controlled room temperature with protection from light is typical. Injectable-grade material should be dispensed in an ISO 7 or better controlled area, with operators wearing appropriate containment because fine particles may be respiratory and dermal irritants. Occupational exposure limits should be derived from no-observed-adverse-effect data; in the absence of a published occupational exposure limit for this exact compound, a conservative banding approach is applied.